AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED REMIBRUTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH REMIBRUTINIB

Registry ID

CLOU064A2306B

Source registry

HEALTH_CANADA

Status

Ongoing

Study type

INTERVENTIONAL

Sponsor

NOVARTIS PHARMACEUTICALS CANADA INC

Start date

2026-04-01

Last update

2026-03-11

Conditions

• ALLERGIES

Related clinical trials

• A PHASE 1B, OPEN-LABEL, EXPLORATORY STUDY EVALUATING THE EFFECTS OF INHALED EPINEPHRINE IN INDIVIDUALS EXPERIENCING SYSTEMIC ALLERGIC REACTIONS DURING ALLERGY TESTING, IMMUNOTHERAPY OR ORAL CHALLENGES
• PREMED-F1: FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE USE OF CETIRIZINE AS A REPLACEMENT FOR DYPHENHYDRAMINE TO PREVENT REACTIONS LINKED TO PACLITAXEL PERFUSION

View on source registry